

## Acknowledgements

We would like to thank Mrs Yvonne Gallistl for her secretarial assistance. The technical assistance of Mrs Bettina Leschnik is also gratefully acknowledged.

## Disclosure of Conflict of Interests

The authors state that they have no conflict of interest.

## References

- Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. *Obes Rev* 2002; **3**: 85–101.
- Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PWF, Levy D, Muller JE, Toffler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. *Thromb Haemost* 2004; **91**: 683–9.
- Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, Manigrasso MR, Basili S, Davi G. Leptin increase is associated with markers of the hemostatic system in obese healthy women. *J Thromb Haemost* 2003; **1**: 2330–4.
- Gallistl S, Sudi KM, Borkenstein M, Troebinger M, Weinhandl G, Muntean W. Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents. *Int J Obes Relat Metab Disord* 2000; **24**: 1459–64.
- Freedman DS, Khan LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS. The relation of childhood BMI to adult adiposity: the Bogalusa Heart Study. *Pediatrics* 2005; **115**: 22–7.
- Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. *Exp Clin Endocrinol Diabetes* 2004; **112**: 378–82.
- Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. *J Thromb Haemost* 2005; **3**: 35–45.
- Berenson GS, Srinivasan SR, Bao W, Newman 3rd WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med* 1998; **338**: 1650–6.
- Mann KG, Brummel K, Butenas S. What is all that thrombin for? *J Thromb Haemost* 2003; **1**: 1504–14.
- Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. *Pathophysiol Haemost Thromb* 2003; **33**: 4–15.
- Pilz S, Horejsi R, Möller R, Almer G, Scharnagl G, Stojakovic T, Dimitrova R, Weihrauch G, Borkenstein M, Maerz W, Schauenstein K, Mangge H. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. *J Clin Endocrinol Metab* 2005; **90**: 4792–6.
- De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. *J Endocrinol Invest* 2002; **25**: 899–904.
- Marutsuka K, Hatakeyama K, Yamashita A, Asada Y. Role of thrombogenic factors in the development of atherosclerosis. *J Atheroscler Thromb* 2005; **12**: 1–8.
- Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. *Lancet* 1993; **342**: 1076–9.
- Sudi KM, Gallistl S, Weinhandl G, Muntean W, Borkenstein MH. Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents. *Metabolism* 2000; **49**: 890–5.
- Ferguson MA, Gutin B, Owens S, Litaker M, Tracy RP, Allison J. Fat distribution and hemostatic measures in obese children. *Am J Clin Nutr* 1998; **67**: 1136–40.
- Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, Fontaine P, Jude B. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. *Thromb Res* 2001; **101**: 367–75.
- Cvirn G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. *J Thromb Haemost* 2003; **1**: 263–8.

# Intermittent mechanical compression for prevention of travellers' thrombosis

M. COPPENS,\* F. F. VAN DOORMAAL,\* A. J. M. SCHREIJER,\*† F. R. ROSENDAAL‡ and H. R. BÜLLER\*

\*Department of Vascular Medicine, Academic Medical Center, Amsterdam; †Department of Clinical Epidemiology, Leiden University Medical Center, Leiden; and ‡Thrombosis and Haemostasis Research Center, Leiden University Medical Center, Leiden, the Netherlands

**To cite this article:** Coppens M, van Doormaal FF, Schreijer AJM, Rosendaal FR, Büller HR. Intermittent mechanical compression for prevention of travellers' thrombosis. *J Thromb Haemost* 2006; **4**: 1836–8.

Correspondence: Michiel Coppens, Department of Vascular Medicine, F4-276, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Tel.: +31 20 5667516; fax: +31 20 6968833; e-mail: m.coppens@amc.nl

Received 13 April 2006, accepted 18 April 2006

Long-haul air travel is associated with coagulation activation and an increased risk of deep vein thrombosis and pulmonary embolism. The overall risk of developing thrombosis is approximately one per 5000 flights lasting more than 4 h [1,2]. This risk is further increased in people with additional risk factors such as inherited thrombophilia, recent surgery and oral

contraceptive use [2,3]. Whether this risk warrants pharmacological prophylaxis in high-risk travellers is controversial, partly due to the concomitant risk of bleeding associated with anticoagulants. Intermittent pneumatic compression devices have been shown to increase venous outflow and to safely reduce the risk of postoperative venous thrombosis with no effect on bleeding [4]. Besides the effects on venous outflow, intermittent compression has also been shown to increase fibrinolytic activity, which may contribute to the anti-thrombotic effect [5].

In the present crossover study, we evaluated the effects of intermittent mechanical compression in six volunteers (four men, mean age 59 years, range 55–64), of whom none had a history of venous thromboembolism or heart failure. Intermittent mechanical compression was exerted by a lightweight novel device (AviaFit™, FlowMedic Ltd, Caesarea, Israel), placed on both calves, and which generates 1 pulse min<sup>-1</sup> with a pressure of 45 mmHg during 7 s. The volunteers were exposed to 4 h of strict seated immobilization on two separate occasions. Half of the group had the devices placed the first day, the others on the second day of investigation, 1 week later.

Effects of intermittent compression were assessed by measurement of venous flow velocity, both proximally and distally of the device, changes of lower extremity volume and by markers of coagulation and fibrinolysis. All measurements were performed, and blood samples taken, immediately prior to, and at the end of, the seated immobilization. Both peak flow velocity and mean flow velocity over a 7.2-s interval in the popliteal vein were measured using duplex ultrasonography. Direction of flow during compression distally from the device was measured in the posterior tibial vein. The increase in lower extremity volume was calculated by measuring the volume immediately before and after immobilization at 30 cm from the ground using a water bath. Prothrombin fragments 1 + 2, tissue type plasminogen activator antigen, D-dimer and von Willebrand factor antigen were determined with standard laboratory assays. Global fibrinolytic capacity,

as described by Giddings *et al.* [6] was measured as a marker of overall activity.

The mean flow velocity in the popliteal vein after 4 h of seated immobilization with intermittent compression was increased almost twofold, as compared to seated immobilization without the device. After adjustment for flow velocity at baseline, the absolute increase was 1.0 cm s<sup>-1</sup> [95% confidence interval (CI%95) -1.1 to 3.1; Table 1]. The contraction of the device induced a flow pulse in the popliteal vein with a peak flow velocity measured at the end of the 4-h observation period of 33.6 cm s<sup>-1</sup>, which was much higher than the peak flow velocity induced by normal inspiration and expiration (5.3 cm s<sup>-1</sup>; Table 1). For comparison, mean peak flow velocity during maximal inspiration without the device is approximately 9 cm s<sup>-1</sup>. Flow direction in the posterior tibial vein during compression was upwards in all subjects. The mean increase in lower-extremity volume induced by seated immobilization was 91 mL without intermittent compression, as compared to 73 mL with intermittent compression respectively. Adjusted for values at baseline, the absolute difference was -20 mL (CI%95 -77 to 36). With regard to laboratory markers of coagulation and fibrinolysis, the mean global fibrinolytic capacity was higher with intermittent compression, as compared to without intermittent compression, with wide confidence limits (adjusted absolute difference 2.5 µg mL<sup>-1</sup>, CI%95 -2.7 to 7.8; Table 1). Other markers of fibrinolysis and coagulation did not show an effect of intermittent compression.

Our objective in this pilot experiment was to assess the potential of the novel device on flow, lower extremity volume, and hemostasis. The findings suggest that this device increases peak flow velocity in the popliteal vein to an extent which cannot be achieved by maximal inspiration. In fact, the device induced a peak flow that was approximately 3-fold higher. Furthermore, the increase in mean flow velocity in between compressions suggested that these pulses may have a carry-over effect that stimulates venous outflow of the lower extremity. There was no indication that the device induced backward

**Table 1** Effects on intermittent mechanical compression on venous flow, lower-extremity volume and coagulation/fibrinolysis after 4 h of seated immobilization without or with intermittent mechanical compression

|   | Mean        |          | Adjusted absolute difference (95%CI)* |
|---|-------------|----------|---------------------------------------|
|   | Without IMC | With IMC |                                       |
| Venous flow   |             |          |                                       |
| Flow velocity popliteal vein (cm s <sup>-1</sup> )          | 1.4         | 2.6      | 1.0 (-1.1 to +3.1)                    |
| Peak flow (cm s <sup>-1</sup> )                             | 5.3         | 33.6     | 28.3 <sup>†</sup> (11.7 to +44.8)     |
| Lower-extremity volume/venous stasis                        |             |          |                                       |
| Volume increase (mL)  | 91          | 73       | -20 (-77 to +36)                      |
| Coagulation/fibrinolysis                                    |             |          |                                       |
| Prothrombin fragments 1 + 2 (nmol L <sup>-1</sup> )         | 0.6         | 0.5      | -0.1 (-0.4 to +0.2)                   |
| Global fibrinolytic capacity (µg mL <sup>-1</sup> )         | 4.0         | 6.1      | 2.5 (-2.7 to +7.8)                    |
| Tissue plasminogen activator antigen (ng mL <sup>-1</sup> ) | 4.7         | 5.3      | 0.6 (-0.6 to +1.7)                    |
| D-dimer (µg mL <sup>-1</sup> )                              | 0.3         | 0.2      | -0.1 (-0.3 to +0.1)                   |
| von Willebrand factor antigen (%)                           | 129         | 125      | -7 (-15 to +1)                        |

IMC, intermittent mechanical compression.

\*Adjusted for values at baseline. <sup>†</sup>Unadjusted absolute difference. IMC, intermittent mechanical compression.

flow. Lower extremity volume measurement after immobilization suggested a beneficial effect of the device. Finally, with the possible exception of the global fibrinolytic capacity, we could not detect any effect on systemic hemostasis.

Our findings warrant further experimental and clinical evaluation as to whether this device may be useful in the setting of prevention of air travel-related thrombosis.

### Acknowledgements

We gratefully acknowledge the assistance of Dr J. C. M. Meijers regarding the laboratory analyses, of M. J. C. Pannekoek regarding the duplex ultrasonography, and of Dr N.S. Gibson, regarding the protocol execution. The devices for intermittent mechanical compression (AviaFit™) were kindly supplied by FlowMedic Ltd.

### Disclosure of Conflict of Interests

The authors state that they have no conflict of interest.

### References

- 1 Kuipers S, Schreijer AJ, Cannegieter SC, Middeldorp S, Buller HR, Rosendaal FR. The absolute risk of venous thrombosis after air travel (WRIGHT study). *J Thromb Haemost* 2005; **3**: P1657.
- 2 Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Buller HR, Rosendaal FR. Activation of coagulation system during air travel: a crossover study. *Lancet* 2006; **367**: 832–8.
- 3 Martinelli I, Taioli E, Battaglioli T, Podda GM, Passamonti SM, Pedotti P, Manucci PM. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. *Arch Intern Med* 2003; **163**: 2771–4.
- 4 Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004; **126**: 338S–400S.
- 5 Chen AH, Frangos SG, Kilaru S, Sumpio BE. Intermittent pneumatic compression devices — physiological mechanisms of action. *Eur J Vasc Endovasc Surg* 2001; **21**: 383–92.
- 6 Giddings JC, Morris RJ, Ralis HM, Jennings GM, Davies DA, Woodcock JP. Systemic haemostasis after intermittent pneumatic compression. Clues for the investigation of DVT prophylaxis and travellers thrombosis. *Clin Lab Haematol* 2004; **26**: 269–73.

## Thromboprophylaxis with graduated compression stockings for elderly inpatients: more evidence is needed

J. LABARERE,\* J.-L. BOSSON,\* M.-A. SEVESTRE,† G. BOGE‡ and B. TERRIAT,§ ON BEHALF OF THE ASSOCIATION POUR LA PROMOTION DE L'ANGIOLOGIE HOSPITALIÈRE

\*THEMAS TIMC-IMAG, UMR CNRS 5525 UJF, Grenoble University Hospital, Grenoble; †Department of Vascular Medicine, Amiens University Hospital, Amiens; ‡Department of Internal Medicine, Montpellier University Hospital, Montpellier; §Department of Vascular Medicine, Dijon University Hospital, Dijon, France

**To cite this article:** Labarere J, Bosson J-L, Sevestre M-A, Boge G, Terriat B, on behalf of the Association pour la Promotion de l'Angiologie Hospitalière. Thromboprophylaxis with graduated compression stockings for elderly inpatients: more evidence is needed. *J Thromb Haemost* 2006; **4**: 1838–40.

Graduated compression stockings are used to prevent deep vein thrombosis (DVT) in elderly patients [1], a setting in which physicians are often reluctant to order anticoagulant-based prophylaxis for fear of bleeding complications. Although their mechanism of action is probably multifactorial, graduated compression stockings exert graded circumferential pressure from distal to proximal segments of the lower limbs, increasing venous outflow and reducing stasis within the leg veins [2]. Their use is recommended only in patients at high risk for

bleeding complications or as an adjunct to anticoagulant-based prophylaxis [3]. The aim of this study was to identify baseline characteristics and treatments associated with the use of graduated compression stockings in elderly patients with restricted mobility.

We analyzed the individual data for 1664 patients, 65 years of age or older, who were enrolled in two cross-sectional studies conducted at 50 hospital-based postacute care facilities in France in 2001 and 2003. Postacute care departments receive patients who typically have complicated conditions and who require specialized care, rehabilitation services, or other services associated with the transition between short-stay hospital care and home. Risk factors and prophylaxis for venous thromboembolism were collected by physicians, using a case report form. Graduated compression stocking users were defined as patients who wore below-knee or thigh-length graduated compression stockings for daytime hours or longer. Given the observational nature of this study, physicians in charge of

Correspondence: Jose Labarere, Unité d'Evaluation Médicale, Pavillon Taillefer, Centre Hospitalier Universitaire BP 217, 38 043 Grenoble cedex 9, France

Tel.: + 33 4 7676 8767; fax: + 33 4 7676 8831; e-mail: jlabarere@chu-grenoble.fr

Received 26 April 2006, accepted 11 May 2006